Physical Activity Declines After Starting GLP-1 Obesity Treatments

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

People taking GLP-1 weight loss drugs like Ozempic started moving less

People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long…

Study finds exercise decreases among people taking GLP-1 medication

Adults with obesity who lost weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.

Exercise declined in patients with obesity after starting a GLP-1

CHICAGO — In patients with obesity, exercise as assessed by wearable-measured activity declined after they initiated GLP-1 receptor agonist therapy, according to findings presented at ENDO 2026. “GLP-1 receptor agonists are now used by millions of adults for weight loss, and we know from prior work that exercise is critical for preserving lean muscle and sustaining long-term weight reduction,”

GLP-1 Therapies Silence Spontaneous Physical Activity

A new study demonstrates that adults managing obesity significantly decrease their physical activity after starting GLP-1 receptor agonist medications.

Physical Activity Declines Among Individuals Using GLP-1 Medications, Study

Recent research presented at ENDO 2026, the Endocrine Society’s annual meeting held in Chicago, Illinois, has unveiled unexpected findings surrounding the use of glucagon-like peptide-1 (GLP-1) receptor agonists in weight loss among adults with obesity. While these medications have been celebrated for their efficacy in reducing body fat, this groundbreaking study reveals a significant unintended […]